Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 3/20 | 0.31 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894764 | 0.84 | PPARG (0.39) | PPARGDPP4GPR84GRIN1GRIN2B | |
| SCHEMBL4011154 | 0.77 | PPARG (0.51) | PPARGDPP4ACHE | |
| SCHEMBL4010555 | 0.75 | PPARG (0.38) | PPARGGPR84GRIN1GRIN2BPTGES | |
| SCHEMBL1891682 | 0.75 | PPARG (0.54) | PPARGACHE | |
| SCHEMBL4010582 | 0.73 | PPARG (0.50) | PPARGACHEPTGES | |
| SCHEMBL1890918 | 0.72 | PPARG (0.51) | PPARG | |
| SCHEMBL12349236 | 0.72 | AGTR1 (0.39) | PPARGACHEPTGES | |
| SCHEMBL1889960 | 0.72 | PPARG (0.40) | PPARGGRIN1GRIN2B | |
| SCHEMBL1893847 | 0.72 | PPARG (0.51) | PPARG | |
| Potassium SCHEMBL1893850 | 0.72 | PPARG (0.51) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009133970-A1 | CRYSTALLINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | WO | disclosed |